{"filing":{"accession_number":"0001714899-26-000081","cik":"0001714899","ticker":"DNLI","company_name":"Denali Therapeutics Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"dnli-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/dnli-20260612.htm"},"events":[{"id":11709,"run_id":10292,"accession_number":"0001714899-26-000081","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.94,"summary":"Denali entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. The transaction is subject to customary closing conditions including Hart-Scott-Rodino review, and the company intends to use proceeds to fund its clinical pipeline.","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8364,"accession_number":"0001714899-26-000081","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Denali entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. This is a material disposition of an asset with significant financial value. The filing explicitly states the transaction is subject to customary closing conditions including Hart-Scott-Rodino review, and the company intends to use proceeds to fund its clinical pipeline, making this a material event affecting the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:03:09.277511+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8365,"accession_number":"0001714899-26-000081","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Denali announced entry into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million gross proceeds. This constitutes a material disposition of an asset with significant financial value. The filing explicitly states the company \"has entered into a definitive agreement to sell\" the PRV, and the transaction is subject to customary closing conditions including Hart-Scott-Rodino review, consistent with M\u0026A activity disclosure requirements under Item 1.01 or 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:03:09.277511+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8364,"accession_number":"0001714899-26-000081","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Denali entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. This is a material disposition of an asset with significant financial value. The filing explicitly states the transaction is subject to customary closing conditions including Hart-Scott-Rodino review, and the company intends to use proceeds to fund its clinical pipeline, making this a material event affecting the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:03:09.277511+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-06-18"},{"id":8365,"accession_number":"0001714899-26-000081","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Denali announced entry into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million gross proceeds. This constitutes a material disposition of an asset with significant financial value. The filing explicitly states the company \"has entered into a definitive agreement to sell\" the PRV, and the transaction is subject to customary closing conditions including Hart-Scott-Rodino review, consistent with M\u0026A activity disclosure requirements under Item 1.01 or 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:03:09.277511+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-06-18"}]}